Comparative Pharmacology
Head-to-head clinical analysis: FINGOLIMOD versus FINGOLIMOD HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINGOLIMOD versus FINGOLIMOD HYDROCHLORIDE.
FINGOLIMOD vs FINGOLIMOD HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.
0.5 mg orally once daily
0.5 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 6–9 days due to enteropathic recirculation and high Vd; clinical context: steady state reached in 1–2 months, duration of immunosuppression persists for weeks after discontinuation.
Clinical Note
moderateFingolimod + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Isavuconazonium
Terminal elimination half-life is approximately 6–9 days; due to extensive tissue distribution, steady-state is reached within 1–2 months of daily dosing.
Primarily via biliary/fecal excretion (81% of dose recovered in feces as metabolites); renal excretion accounts for <2.5% of unchanged drug.
Primarily hepatic metabolism (CYP4F2) with subsequent biliary/fecal elimination (81% of total clearance); renal excretion accounts for <2.5% of unchanged drug.
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator
"The metabolism of Isavuconazonium can be decreased when combined with Fingolimod."